Study included more than 1000 chemonaïve patients
across all NSCLC histologies

44% of patients were squamous

  • Histology of primary diagnosis1
  • Age2
  • Smoking status1
  • Stage at randomization1
  • ECOG PS1
Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics

Patients were well balanced across treatment arms

Study included more than 1000 chemonaïve patients across all NSCLC histologies

44% of patients were squamous

  • Histology of primary diagnosis1
  • Age2
  • Smoking status1
  • Stage at randomization1
  • ECOG PS1
Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics Non-small cell lung cancer patient characteristics

Patients were well balanced across treatment arms

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.